F-star

F-star is committed to delivering life-changing treatments for the estimated 80% of patients whose cancer fails to have a durable response to immunotherapies.

F-star is committed to delivering life-changing treatments for the estimated 80% of patients whose cancer fails to have a durable response to immunotherapies.

Our novel technology platform of tetravalent mAb2 bispecific antibodies have a natural human antibody format. This allows for a straightforward manufacturing process, and may provide a favorable safety profile and strong biological potency. Multiple clinical trials are underway.

Our product candidates are designed to simultaneously address multiple immune-evasion pathways that limit the effect of existing therapies. These are potentially first- and best-in-class drug candidates for patients with cancer who have few other options. F-star has over 500 granted and pending patents related to our platform technology and product pipeline.

Stay up to date with F-star

Login or create a free user account to follow this company and see updates on your dashboard.

Create account